Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer Clinical Trial

Official title:

A Non-randomized, Open-label, Prospective, Single-center Study of Apatinib Mesylate Tablet as Third-line and Later Therapy in Patients With Small Cell Cancer（SCLC）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02995187
• Other study ID #: CH-L-061
• Status: Recruiting
• Phase: Phase 2
• First received: December 14, 2016
• Last updated: September 4, 2017
• Start date: December 2016
• Est. completion date: September 2018

Study information

• Verified date: September 2017
• Source: Chinese Academy of Medical Sciences
• Contact: Yutao Liu, M.D.
• Phone: +8613911901165
• Email: 13911901165[@]139.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib for third-line and later treatment of patients with small cell lung cancer.

Description:

Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE)and second-line therapy with topotecan has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and 2-year survival is less than 10%. There is no standard treatment recommendation for this group of patients who failed to second-line therapy and had good performance status. Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine. And this clinical trial is designed to prospectively investigate the efficacy and safety of apatinib in recurrent SCLC patients in our center.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: September 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. 18 years to 75 years;

2. Had a histologically or cytologically confirmed diagnosis of SCLC;

3. Had received at least 2 lines chemotherapy regimen and must include basis of the platinum regimen after which disease diagnosed;

4. Have not received VEGFR-TKI;

5. Had a life expectancy of at least 3 months;

6. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2;

7. Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1), larger than 10 mm in diameter by spiral CT scan;

8. Adequate hepatic, renal, heart, and hematologic functions (hemoglobin =90g/L, platelets = 80×10^9/L, neutrophils = 1.5×10^9/L, total bilirubin within 1.5×the upper limit of normal(ULN), and b) ALT and AST=2.5×the ULN (If liver metastases, serum transaminase=5×the ULN), serum creatine = 1.25 x ULN, creatinine clearance rate > 45ml/min;

9. For women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug;

10. Signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion Criteria:

1. Patients with non-small cell lung cancer;

2. Imaging (CT or MRI) results indicate that the existence of central tumors locally invading the large vessel could be detected, or apparent pulmonary cavity or necrotizing tumors;

3. Patients with clinical symptoms of brain metastases or meningeal metastasis;

4. Patients with poor-controlled arterial hypertension (systolic pressure = 140 mmHg and/or diastolic pressure = 90 mm Hg) despite standard medical management;

5. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QT interval male = 450 ms, female = 470 ms). Grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria or echocardiography check: left ventricular ejection fraction (LVEF)<50%;

6. Coagulant function abnormality (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT ULN > 1.5), with bleeding tendency or is treated with thrombolysis and anticoagulation;

7. Patients whose routine urine tests indicate that urine protein = ++ or verifies that the 24-h urine protein quantitation = 1.0 g;

8. Patients who received major surgical operations or experienced severe traumatic injuries, bone fracture, or ulcers within 4 weeks before screening;

9. Patients who had obvious hemoptysis within 2 months before screening, or experienced daily hemoptysis with a volume more than half a tea spoon (2.5ml) or above; Patients who experienced bleeding symptoms of clinical significance , or with confirmed bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or vasculitis, etc;

10. Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening;

11. Allergic to any ingredients of Apatinib;

12. Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• Apatinib Mesylate tablet
Apatinib 500 mg in tablet once daily

Locations

Country	Name	City	State
China	Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	tumor phosphorylated VEGFR2 (p-VEGFR2) expressions		baseline
Primary	Progression-free survival		up to 3 years
Secondary	Overall survival		up to 3 years
Secondary	Disease Control Rate		up to 3 years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0		up to 3 years